Merck and Kelun-Biotech announced positive Phase 3 trial results for their sac-TMT and Keytruda combination in NSCLC, significantly improving progression-free survival. This data, published in a top medical journal, positions the combination as a potential new standard of care, boosting both companies' oncology pipelines.
Merck and Kelun-Biotech reported highly positive Phase 3 results for their sac-TMT and Keytruda combination in advanced NSCLC, significantly outperforming the control arm. This is a major win for both companies, as it validates their oncology pipeline and positions the combination as a potential new blockbuster treatment in a large market. For Merck, it reinforces the value of Keytruda and its strategic partnerships, while for Kelun-Biotech, it highlights their innovative ADC technology. Short-term, this could lead to increased investor confidence and potential stock price appreciation for both companies. Long-term, successful regulatory approval and commercialization would significantly boost revenue and market share in the competitive NSCLC treatment landscape, impacting other oncology players.